Study of Durvalumab Given with Chemoradiation Therapy in Patients with Unresectable Non-small Cell Lung Cancer

Trial Identifier: D933KC00001
Sponsor: AstraZeneca
Start Date: March 2018
Primary Completion Date: September 2023
Study Completion Date: March 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Spanish Translation
Korean Translation
Thai Translation
Turkish Translation
Vietnamese Translation
Cebuano Translation
Czech Translation
Gujarati Translation
Hindi Translation
Hungarian Translation
Ilocano Translation
Japanese Translation
Kannada Translation
Malayalam Translation
Marathi Translation
Polish Translation
Portuguese Translation
Russian Translation
Tamil Translation
Telugu Translation
Tagalog (Philippines) Translation

Trial Locations